US 11,851,682 B2
Brown fat cell compositions and methods
Francisco Javier Silva, Melville, NY (US); Mark Weinreb, Melville, NY (US); Amit N. Patel, Salt Lake City, UT (US); and David A. Bull, Salt Lake City, UT (US)
Assigned to BIORESTORATIVE THERAPIES, INC., Melville, NY (US)
Filed by BioRestorative Therapies, Inc., Melville, NY (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,218.
Application 17/348,218 is a continuation of application No. 15/910,625, filed on Mar. 2, 2018, granted, now 11,066,646.
Application 15/910,625 is a continuation of application No. 13/932,468, filed on Jul. 1, 2013, granted, now 10,597,638, issued on Mar. 24, 2020.
Application 13/932,468 is a continuation of application No. 13/536,564, filed on Jun. 28, 2012, abandoned.
Claims priority of provisional application 61/632,516, filed on Jan. 25, 2012.
Claims priority of provisional application 61/632,122, filed on Jan. 18, 2012.
Claims priority of provisional application 61/502,508, filed on Jun. 29, 2011.
Prior Publication US 2021/0309972 A1, Oct. 7, 2021
Int. Cl. C12N 5/0775 (2010.01); C12N 5/077 (2010.01); G01N 33/50 (2006.01); A61K 35/35 (2015.01); A61K 35/28 (2015.01)
CPC C12N 5/0667 (2013.01) [A61K 35/35 (2013.01); C12N 5/0653 (2013.01); G01N 33/502 (2013.01); G01N 33/5044 (2013.01); A61K 35/28 (2013.01); C12N 2500/84 (2013.01); C12N 2500/98 (2013.01); C12N 2501/01 (2013.01); C12N 2501/02 (2013.01); C12N 2501/33 (2013.01); C12N 2501/385 (2013.01); C12N 2501/39 (2013.01); C12N 2501/395 (2013.01); C12N 2506/1384 (2013.01); Y02A 50/30 (2018.01)] 14 Claims
 
1. A method of identifying a compound that modifies metabolic activity of a population of human brown fat adipocytes, the method comprising:
differentiating a human stem cell that is removed from human brown adipose tissue into a population of differentiated human brown fat adipocytes, the differentiating performed in a hypoxic environment of 0 to about 5% oxygen and in a differentiation medium not comprising a xenogenic animal product wherein the differentiation medium comprises fibronectin type III domain-containing protein 5 (FNDC5), insulin, dexamethasone, isobutylmethylxanthine, indomethacin, triiodothyronine (T3), rosiglitazone, and 0.5 to 20% human platelet lysate;
contacting the population of differentiated human brown fat adipocytes with the compound;
determining metabolic activity of the population of differentiated human brown fat adipocytes in the presence of the compound; and
comparing the metabolic activity of the population of differentiated human brown fat adipocytes in the presence of the compound to metabolic activity of the population of differentiated human brown fat adipocytes in the absence of the compound;
wherein the difference between the metabolic activity of the population of differentiated human brown fat adipocytes in the presence of the compound and the metabolic activity of the population of differentiated human brown fat adipocytes in the absence of the compound identifies compounds that modify the metabolic activity of the population of differentiated human brown fat adipocytes.